

CLAIMS

1. A peptide, characterized in that it consists of a sequence which includes the juxtamembrane domain of the cytoplasmic domain of amyloid precursor protein (β APP) (one-letter code), and which are selected from the group consisting of the sequences $Y_1KQYTSIHGGY_0$ (SEQ ID NO: 2), $Y_1KKQYTSIHGGY_0$ (SEQ ID NO: 3) and $Y_1KKKQYTSIHGGY_0$ (SEQ ID NO: 4), in which Y_0 is null or represents V, VV, VVE VVEV or VVEVD and Y_1 represents an internalization and addressing peptide derived from the 3rd helix of homeodomains, and from structurally related peptides.
2. The peptide as claimed in claim 1, characterized in that said internalization and addressing peptide corresponds to the sequence $X_1X_2X_3X_4X_5X_6X_7X_8X_9X_{10}X_{11}X_{12}X_{13}X_{14}X_{15}X_{16}$, in which $X_1, X_2, X_3, X_4, X_5, X_6, X_7, X_8, X_9, X_{10}, X_{11}, X_{12}, X_{13}, X_{14}, X_{15}$ and X_{16} each represent an α -amino acid, 6 to 10 of said amino acids being hydrophobic and X_6 representing a tryptophan.
3. The peptide as claimed in claim 1 or claim 2, characterized in that the sequence Y_1 corresponds to the sequence KQIKIWFQNRMRMKWKK (SEQ ID NO: 5).
4. The use of a peptide comprising the juxtamembrane domain of the cytoplasmic domain of amyloid precursor protein (APP), for selecting and screening products capable of inhibiting apoptosis.
5. The use as claimed in claim 4, characterized in that said peptide is combined with an internalization peptide selected from the group consisting of internalization peptides capable of crossing the blood-brain barrier.

- 19 -

6. The use as claimed in either of claims 4 and 5, characterized in that said peptide is selected from the group consisting of the sequences (one-letter code) Y₁KQYTSIH₀HGY₀ (SEQ ID NO: 2), Y₁KKQYTSIH₀HGY₀ (SEQ ID NO: 3) and Y₁KKKQYTSIH₀HGY₀ (SEQ ID NO: 4), in which Y₀ is null or represents V, VV, VVE VVEV or VVEVD and Y₁ is null or represents an internalization and addressing peptide derived from the 3rd helix of homeodomains, and from structurally related peptides.
7. The use as claimed in any one of claims 4 to 6, characterized in that said internalization peptide corresponds to the sequence X₁X₂X₃X₄X₅X₆X₇X₈X₉X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅X₁₆, in which X₁, X₂, X₃, X₄, X₅, X₆, X₇, X₈, X₉, X₁₀, X₁₁, X₁₂, X₁₃, X₁₄, X₁₅ and X₁₆ each represent an α -amino acid, 6 to 10 of said amino acids being hydrophobic and X₆ representing a tryptophan.
8. The use of cells, into which a peptide as defined in claims 4 to 7 has been internalized, for selecting and screening products capable of inhibiting apoptosis.
9. A method for screening and selecting products capable of inhibiting apoptosis, characterized in that it comprises:
- bringing the potential inhibitor into contact with a cell into which a peptide as defined in claims 4 to 7 has been internalized, and
 - measuring cleavage of DNA or of actin or measuring the p20 subunit of caspase 3.

- 20 -

10. The use of a peptide as defined in claims 4 to 7,
for preparing an anticancer medicinal product.
- 5 11. A peptide, characterized in that it is selected
from the group consisting of the sequences (one-
letter code) $Y_1KQYTSIHG Y_0$ (SEQ ID NO: 2) and
 $Y_1KKQYTSIHG Y_0$ (SEQ ID NO: 3), in which Y_0 is null
or represents V, VV, VVE VVEV or VVEVD and Y_1 is
10 null, and of the peptide of formula $Y_1KKKQYTSIHG Y_0$
(SEQ ID NO: 4), in which Y_0 represents VVEVD and Y_1
is null.